Mode	NNP
of	IN
action	NN
of	IN
nintedanib	NN
in	IN
the	DT
treatment	NN
of	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
a	DT
progressive	JJ
and	CC
ultimately	RB
fatal	JJ
disease	NN
characterised	VBN
by	IN
fibrosis	NN
of	IN
the	DT
lung	NN
parenchyma	NN
and	CC
loss	NN
of	IN
lung	NN
function	NN
.	.

Although	IN
the	DT
pathogenic	JJ
pathways	NNS
involved	VBN
in	IN
IPF	NN
have	VBP
not	RB
been	VBN
fully	RB
elucidated	VBN
,	,
IPF	NN
is	VBZ
believed	VBN
to	TO
be	VB
caused	VBN
by	IN
repetitive	JJ
alveolar	JJ
epithelial	JJ
cell	NN
injury	NN
and	CC
dysregulated	VBN
repair	NN
,	,
in	IN
which	WDT
there	EX
is	VBZ
uncontrolled	JJ
proliferation	NN
of	IN
lung	NN
fibroblasts	NNS
and	CC
differentiation	NN
of	IN
fibroblasts	NNS
into	IN
myofibroblasts	NNS
,	,
which	WDT
excessively	RB
deposit	NN
extracellular	JJ
matrix	NN
(	(
ECM	NN
)	)
proteins	NNS
in	IN
the	DT
interstitial	JJ
space	NN
.	.

A	DT
number	NN
of	IN
profibrotic	JJ
mediators	NNS
including	VBG
platelet-derived	JJ
growth	NN
factor	NN
(	(
PDGF	NN
)	)
,	,
fibroblast	NN
growth	NN
factor	NN
(	(
FGF	NN
)	)
and	CC
transforming-growth-factor-b	NN
are	VBP
believed	VBN
to	TO
play	VB
important	JJ
roles	NNS
in	IN
the	DT
pathogenesis	NN
of	IN
IPF	NN
.	.

Nintedanib	NNP
is	VBZ
a	DT
potent	JJ
small	JJ
molecule	NN
inhibitor	NN
of	IN
the	DT
receptor	NN
tyrosine	NN
kinases	NNS
PDGF	NN
receptor	NN
,	,
FGF	NN
receptor	NN
and	CC
vascular-endothelial-growth-factor	NN
receptor	NN
.	.

Data	NNS
from	IN
in	FW
vitro	FW
studies	NNS
have	VBP
shown	VBN
that	IN
nintedanib	NN
interferes	VBZ
with	IN
processes	NNS
active	JJ
in	IN
fibrosis	NN
such	JJ
as	IN
fibroblast	NN
proliferation	NN
,	,
migration	NN
and	CC
differentiation	NN
,	,
and	CC
the	DT
secretion	NN
of	IN
ECM	NNP
.	.

In	IN
addition	NN
,	,
nintedanib	NN
has	VBZ
shown	VBN
consistent	JJ
anti-fibrotic	JJ
and	CC
anti-inflammatory	JJ
activity	NN
in	IN
animal	NN
models	NNS
of	IN
lung	NN
fibrosis	NN
.	.

These	DT
data	NNS
provide	VBP
a	DT
strong	JJ
rationale	NN
for	IN
the	DT
clinical	JJ
efficacy	NN
of	IN
nintedanib	NN
in	IN
patients	NNS
with	IN
IPF	NN
,	,
which	WDT
has	VBZ
recently	RB
been	VBN
demonstrated	VBN
in	IN
phase	NN
III	CD
clinical	JJ
trials	NNS
.	.

